Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses.
bioresorbable
chronic rhinosinusitis
corticosteroid
drug delivery
drug matrix
mometasone furoate
mucosa
nasal implant
pharmacokinetics
sustained release
Journal
American journal of rhinology & allergy
ISSN: 1945-8932
Titre abrégé: Am J Rhinol Allergy
Pays: United States
ID NLM: 101490775
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
pubmed:
1
9
2021
medline:
4
2
2022
entrez:
31
8
2021
Statut:
ppublish
Résumé
Intranasal corticosteroid sprays (INCSs) used to treat chronic rhinosinusitis are suboptimal due to limited penetration into the middle meatus, rapid clearance, and poor patient compliance. A bioresorbable drug matrix, developed with the XTreo To evaluate the in vitro drug release and in vivo pharmacokinetics of novel mometasone furoate (MF) matrices in a rabbit dorsal maxillary osteotomy model. XTreo XTreo The XTreo
Sections du résumé
BACKGROUND
BACKGROUND
Intranasal corticosteroid sprays (INCSs) used to treat chronic rhinosinusitis are suboptimal due to limited penetration into the middle meatus, rapid clearance, and poor patient compliance. A bioresorbable drug matrix, developed with the XTreo
OBJECTIVE
OBJECTIVE
To evaluate the in vitro drug release and in vivo pharmacokinetics of novel mometasone furoate (MF) matrices in a rabbit dorsal maxillary osteotomy model.
METHODS
METHODS
XTreo
RESULTS
RESULTS
XTreo
CONCLUSION
CONCLUSIONS
The XTreo
Identifiants
pubmed: 34463546
doi: 10.1177/19458924211039197
doi:
Substances chimiques
Nasal Sprays
0
Mometasone Furoate
04201GDN4R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM